Sumeet K. Asrani M.D.

Posted January 15th 2020

Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis.

Sumeet K. Asrani M.D.
Sumeet K. Asrani M.D.

Asrani, S. K., J. Trotter, J. Lake, A. Ahmed, A. Bonagura, A. Cameron, A. DiMartini, S. Gonzalez, G. Im, P. Martin, P. Mathurin, J. Mellinger, J. P. Rice, V. H. Shah, N. Terrault, A. Wall, S. Winder and G. Klintmalm (2020). “Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis.” Liver Transpl 26(1): 127-140.

Full text of this article.

Liver transplantation (LT) for alcohol associated hepatitis (AH) remains controversial. We convened a consensus conference to examine various aspects of LT for AH. The goal was not to unequivocally endorse LT for AH; instead, it was to propose recommendations for programs that perform or plan to perform LT for AH. Criteria were established to determine candidacy for LT in the setting of AH and included the following: (1) AH patients presenting for the first time with decompensated liver disease that are nonresponders to medical therapy without severe medical or psychiatric comorbidities; (2) a fixed period of abstinence prior to transplantation is not required; and (3) assessment with a multidisciplinary psychosocial team, including a social worker and an addiction specialist/mental health professional with addiction and transplantation expertise. Supporting factors included lack of repeated unsuccessful attempts at addiction rehabilitation, lack of other substance use/dependency, acceptance of diagnosis/insight with a commitment of the patient/family to sobriety, and formalized agreement to adhere to total alcohol abstinence and counseling. LT should be avoided in AH patients who are likely to spontaneously recover. Short-term and longterm survival comparable to other indications for LT must be achieved. There should not be further disparity in LT either by indication, geography, or other sociodemographic factors. Treatment of alcohol-use disorders should be incorporated into pre- and post-LT care. The restrictive and focused evaluation process described in the initial LT experience for AH worldwide may not endure as this indication gains wider acceptance at more LT programs. Transparency in the selection process is crucial and requires the collection of objective data to assess outcomes and minimize center variation in listing. Oversight of program adherence is important to harmonize listing practices and outcomes.


Posted January 15th 2020

Liver transplantation and chronic disease management: Moving beyond patient and graft survival.

Sumeet K. Asrani M.D.
Sumeet K. Asrani M.D.

Serper, M. and S. K. Asrani (2019). “Liver transplantation and chronic disease management: Moving beyond patient and graft survival.” Am J Transplant Dec 17. [Epub ahead of print].

Full text of this article.

With advances in surgical techniques, multidisciplinary care and immunosuppression, patient and graft survival continue to improve in liver transplantation (LT). Excellent patient and graft survival have translated into an aging liver transplant recipient (LTRs) cohort that resembles a general chronic disease population. LTRs are becoming more medically complex related to LT indication (e.g. non-alcoholic fatty liver disease) and with increased prevalence of relevant chronic conditions such as chronic kidney disease.(Excerpt from text of this editorial.)


Posted December 15th 2019

Meeting Report: The Dallas consensus conference on liver transplantation for alcohol related hepatitis.

Sumeet K. Asrani M.D.
Sumeet K. Asrani M.D.

Asrani, S. K., J. Trotter, J. Lake, A. Ahmed, A. Bonagura, A. Cameron, A. DiMartini, S. Gonzalez, G. Im, P. Martin, P. Mathurin, J. Mellinger, J. P. Rice, V. H. Shah, N. Terrault, A. Wall, S. Winder and G. Klintmalm (2019). “Meeting Report: The Dallas consensus conference on liver transplantation for alcohol related hepatitis.” Liver Transpl Nov 19. [Epub ahead of print].

Full text of this article.

Liver transplantation (LT) for alcohol related hepatitis (AH) remains controversial. We convened a consensus conference to examine various aspects of LT for AH. The goal was not to unequivocally endorse LT for AH; instead it was to propose recommendations for programs that perform or plan to perform LT for AH. Criteria were established to determine candidacy for LT in the setting of AH and included the following: (1) AH patients presenting for the first time with decompensated liver disease that are non-responders to medical therapy without severe medical or psychiatric comorbidities (2) A fixed period of abstinence prior to transplantation is not required (3) Assessment with a multidisciplinary psychosocial team including a social worker and a addiction specialist/mental health professional with addiction and transplantation expertise. Supporting factors include lack of repeated unsuccessful attempts at addiction rehabilitation, lack of other substance use/dependency, acceptance of diagnosis/insight with commitment of patient/family to sobriety and formalized agreement to adhere to total alcohol abstinence and counseling. LT should be avoided in AH patients that are likely to spontaneously recover. Short- and long-term survival comparable to other indications for LT must be achieved. There should not be further disparity in LT either by indication, geography, or other sociodemographic factors. Treatment of alcohol use disorders should be incorporated into pre and post-LT care. The restrictive and focused evaluation process described in the initial LT experience for AH worldwide may not endure as this indication gains wider acceptance at more LT programs. Transparency in selection process is crucial with collection of objective data to assess outcomes and minimize center variation in listing. Oversight of program adherence is important to harmonize listing practices and outcomes.


Posted November 15th 2019

Incidence and Risk Factors Associated With 30-Day Readmission for Alcoholic Hepatitis.

Sumeet K. Asrani M.D.
Sumeet K. Asrani M.D.

Garg, S. K., S. Sarvepalli, D. Singh, I. Obaitan, T. Peeraphatdit, L. Jophlin, S. K. Asrani, V. H. Shah and M. D. Leise (2019). “Incidence and Risk Factors Associated With 30-Day Readmission for Alcoholic Hepatitis.” J Clin Gastroenterol 53(10): 759-764.

Full text of this article.

BACKGROUND: Alcohol abuse and liver disease are associated with high rates of 30-day hospital readmission, but factors linking alcoholic hepatitis (AH) to readmission are not well understood. We aimed to determine the incidence rate of 30-day readmission for patients with AH and to evaluate potential predictors of readmission. METHODS: We used the Nationwide Readmissions Database to determine the 30-day readmission rate for recurrent AH between 2010 and 2014 and examined trends in readmissions during the study period. We also identified the 20 most frequent reasons for readmission. Multivariate survey logistic regression analysis was used to identify factors associated with 30-day readmission. RESULTS: Of the 61,750 index admissions for AH, 23.9% were readmitted within 30-days. The rate of readmission did not change significantly during the study period. AH, alcoholic cirrhosis, and hepatic encephalopathy were the most frequent reasons for readmission. In multivariate analysis female sex, leaving against medical advice, higher Charlson comorbidity index, ascites, and history of bariatric surgery were associated with earlier readmissions, whereas older age, payer type (private or self-pay/other), and discharge to skilled nursing-facility reduced this risk. CONCLUSIONS: The 30-day readmission rate in patients with AH was high and stable during the study period. Factors associated with readmission may be helpful for development of consensus-based expert guidelines, treatment algorithms, and policy changes to help decrease readmission in AH.


Posted November 15th 2019

Accurate assessment of renal function in cirrhosis.

Sumeet K. Asrani M.D.
Sumeet K. Asrani M.D.

Asrani, S. K. (2019). “Accurate assessment of renal function in cirrhosis.” Hepatology Oct 25. [Epub ahead of print].

Full text of this article.

First, serum creatinine, sodium and estimated glomerular filtration rate (GFR) are all imperfect surrogates of renal function in patients with cirrhosis. This is especially true in patients with decompensated liver disease, whereby the influence of extrahepatic factors may impede accurate estimation. Often, renal function is dependent on where the patient lies on the acute kidney injury/chronic kidney disease continuum, the degree of liver dysfunction and other relevant patient characteristics. Developing an estimating equation for each and every subset of cirrhotic is untenable.